|
 Nubeqa, also known as darolutamide, improved overall survival in a
combination with standard care when compared to standard care alone,
which was the primary goal of the trial, the German company said in
a statement on Friday.
The trial read-out could pave the way for an enlarged market as
Nubeqa is already approved in non-metastatic prostate cancer that
cannot be treated with standard hormone therapy.
Bayer, which is paying billions to settle U.S. claims its Roundup
weedkiller caused cancer, needs to strengthen its drug development
pipeline as its two pharmaceutical best-sellers, stroke prevention
pill Xarelto and eye drug Eylea, face a decline in sales in a few
years.
[to top of second column] |
Nubeqa is one of three Bayer
prescription drugs that the company expects to
generate more than $1 billion in peak annual
sales, known in the industry as blockbusters,
alongside kidney disease treatment finerenone
and menopausal symptoms relief elinzanetant.
Details of the trial would be presented at an as
yet undisclosed medical conference, it added.
(Reporting by Ludwig BurgerEditing by Paul
Carrel)
[© 2021 Thomson Reuters. All rights
reserved.] Copyright 2021 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content |
